Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | Director | December 22, 2020 | December 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibitor Therapeutics, Inc.
Report date December 22, 2020 · Filed December 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2030-12-22 | Direct | 754,839 |
Reported balance
After 2020-12-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-22 · Grant · Acquired 754,839 · Balance 754,839 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2020 Filed Dec 28, 2020 21:30 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock Option · Derivative | 754,839 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0000899243-20-035195 · doc4.xml · derivative · entry 1 Martin Robert Daniel · CIK 0001509322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 754,839 Underlying: Common Stock · 754,839 shares Expires 2030-12-22 Read SEC document |
| March 20, 2020 Filed Mar 24, 2020 13:00 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock Option · Derivative | 1,000,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0000899243-20-009309 · doc4.xml · derivative · entry 1 Martin Robert Daniel · CIK 0001509322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-03-20 Read SEC document |
| February 03, 2019 Filed Feb 6, 2019 00:57 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock Option · Derivative | 657,895 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0000899243-19-002714 · doc4.xml · derivative · entry 1 Martin Robert Daniel · CIK 0001509322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657,895 Underlying: Common Stock · 657,895 shares Expires 2029-02-03 Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 22:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock | 60,000 | $0.08 | $4,800.00 |
DisclosureSEC source: 0000899243-18-031719 · doc4.xml · nonDerivative · entry 1 Martin Robert Daniel · CIK 0001509322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,000 Read SEC document |
| March 13, 2018 Filed Mar 16, 2018 00:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock Option · Derivative | 56,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0000899243-18-007662 · doc4.xml · derivative · entry 2 Martin Robert Daniel · CIK 0001509322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2028-03-13 Read SEC document |
| March 13, 2018 Filed Mar 16, 2018 00:15 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantCommon Stock Option · Derivative | 253,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0000899243-18-007662 · doc4.xml · derivative · entry 1 Martin Robert Daniel · CIK 0001509322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,000 Underlying: Common Stock · 253,000 shares Expires 2028-03-13 F1 · security: These options were granted subject to the approval of the majority stockholder of the registrant pursuant to an agreement between the majority stockholder and the registrant. In the event that the majority stockholder does not approve the option grant, the options will be canceled. Read SEC document |
| May 04, 2017 Filed Jul 19, 2017 23:43 UTC | Inhibitor Therapeutics, Inc. HPPI · Entity 7783 | GrantRestricted Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018594 · doc4.xml · derivative · entry 1 Martin Robert Daniel · CIK 0001509322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The RSUs were issued to the reporting person on May 4, 2017, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The RSUs will vest in full on January 1, 2018, provided that if such vesting date is not during an open trading window, then such RSUs will vest on the first day that thereafter that is during an open trading window. F2 · derivative.expiration_date: The RSUs were issued to the reporting person on May 4, 2017, pursuant to a grant under the issuer's 2014 Equity Incentive Plan. The RSUs will vest in full on January 1, 2018, provided that if such vesting date is not during an open trading window, then such RSUs will vest on the first day that thereafter that is during an open trading window. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.